Antibody-Drug Conjugates Containing Payloads from Marine Origin [PDF]
Marine Drugs, 2022 Antibody-drug conjugates (ADCs) are an important class of therapeutics for the treatment of cancer. Structurally, an ADC comprises an antibody, which serves as the delivery system, a payload drug that is a potent cytotoxin that kills cancer cells, and a ...
Iván Cheng-Sánchez +4 more
doaj +2 more sources
Click Chemistry and Multicomponent Reaction for Linker Diversification of Zinc Dipicolylamine-Based Drug Conjugates [PDF]
Frontiers in Chemistry, 2022 An efficient Ugi multicomponent reaction with strain promoted azide-alkyne cycloaddition protocol has been utilized in concert or independently to prepare a small family of bioactive zinc(II) dipicolylamine (ZnDPA)-based SN-38 conjugates. With sequential
Ching-Hua Tsai +7 more
doaj +2 more sources
Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions [PDF]
Pharmacological ResearchDrug conjugates are obtained from tumor-located vectors connected to cytotoxic agents via linkers, which are designed to deliver hyper-toxic payloads directly to targeted cancer cells.
Cuiping Li +10 more
doaj +2 more sources
Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C‐Lock linker [PDF]
Cancer Medicine, 2019 Antibody‐drug conjugates (ADCs) belong to a promising class of biopharmaceuticals in which target‐killing of tumor cells was achieved by marrying the potency of the cytotoxic payload with the tumor specificity of the antibody.
Baoying Shi +10 more
doaj +2 more sources
A Novel Dual-Payload ADC for the Treatment of HER2+ Breast and Colon Cancer [PDF]
Pharmaceutics, 2023 Antibody-drug conjugates (ADCs) have demonstrated a great therapeutic potential against cancer due to their target specificity and cytotoxicity. To exert a maximum therapeutic effect on cancerous cells, we have conjugated two different payloads to ...
Candice Maria Mckertish, Veysel Kayser
doaj +2 more sources
Current Cancer Therapy Reviews, 2016 Over the last decade, Antibody Drug Conjugates (ADCs) have gained a great success due to their documented clinical efficacy and manageable toxicity. Generally the word "drug" is associated with a che-motherapeutic drug, however "drug" can also be associated with other cy-totoxic payloads such as radionuclides, termed more specifically, Anti-body ...
Caroline Rousseau +2 more
exaly +4 more sources
Clinical Pharmacology and Translational Science Considerations in the Development of Dual‐Payload Antibody Drug Conjugates [PDF]
Clinical and Translational ScienceAntibody‐drug conjugates (ADCs) have evolved in the last decade or two from carrying a single chemotherapy payload to carrying highly potent tubulin inhibitors and DNA damaging agents.
Paulien Ravenstijn +5 more
doaj +2 more sources
Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents [PDF]
PharmaceuticalsADCs have emerged as a promising class of therapeutics, combining the targeting specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. Although the majority of approved ADCs are still based on microtubule binder payloads,
Barbara Valsasina +3 more
doaj +2 more sources
Extracellular payload release from non-internalizing antibody–drug conjugates: mechanisms and linker technologies [PDF]
Drug DeliveryAntibody‒drug conjugates (ADCs) have taken on a significant role in precision oncology. These molecules, referred to as 'biological missiles', can deliver cytotoxic drugs directly to cancer cells.
Chenxi Feng +7 more
doaj +2 more sources
A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization [PDF]
Clinical Cancer Research, 2019 Abstract Purpose: HER3 is a compelling target for cancer treatment; however, no HER3-targeted therapy is currently clinically available. Here, we produced U3-1402, an anti-HER3 antibody–drug conjugate with a topoisomerase I inhibitor exatecan derivative (DXd), and systematically investigated ...
Toshinori Agatsuma +2 more
exaly +3 more sources